KBC Group NV Has $39.46 Million Stock Holdings in DaVita Inc. $DVA

KBC Group NV decreased its position in shares of DaVita Inc. (NYSE:DVA) by 40.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 256,758 shares of the company’s stock after selling 177,453 shares during the quarter. KBC Group NV’s holdings in DaVita were worth $39,461,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. NewEdge Advisors LLC boosted its position in shares of DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares during the period. Cerity Partners LLC increased its position in shares of DaVita by 7.0% in the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after buying an additional 172 shares in the last quarter. Bank of Nova Scotia raised its stake in DaVita by 3.8% during the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock worth $686,000 after buying an additional 176 shares during the period. Finally, Natixis lifted its holdings in DaVita by 80.9% during the second quarter. Natixis now owns 7,297 shares of the company’s stock worth $1,039,000 after acquiring an additional 3,264 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The SEC filing for this sale provides additional information. 1.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on DVA shares. Truist Financial boosted their target price on DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. UBS Group lifted their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and increased their target price for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, DaVita has an average rating of “Hold” and an average target price of $216.50.

DaVita Trading Down 1.2%

Shares of NYSE DVA opened at $234.16 on Tuesday. The company has a fifty day moving average price of $210.65 and a 200 day moving average price of $165.70. The firm has a market cap of $15.03 billion, a PE ratio of 21.72, a PEG ratio of 0.78 and a beta of 0.88. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $239.64.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same quarter last year, the business posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts forecast that DaVita Inc. will post 15.07 EPS for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.